Eliminating epidemic meningitis as a public health problem in sub-Saharan Africa

Building a Global Partnership to bring a New Vaccine to Patients: MenAfriVac

Drugs for Neglected Diseases initiative (DNDi)
A decade of R&D for Neglected Diseases in Africa
4-5 June 2013, Nairobi - Kenya

Dr. Mamoudou HAROUNA DJINGAREY
MVP Coordinator WHO/AFRO
Epidemic meningitis in Africa: 1948-2012

Disease burden

Reported cases

Meningitis belt

Year

MVP is a partnership between WHO and PATH

Confidential & Proprietary Information
The Meningitis Vaccine Project (MVP)

Early development

• 1996 largest reported epidemic in the African meningitis belt: > 250,000 cases & 25,000 deaths
• Oct 1996 Ouagadougou: Meeting and Appeal from African Ministries of Health
• A partnership between WHO and PATH was established
• June 2001, the Bill & Melinda Gates Foundation agreed to fund MVP
  ➢ Goal of eliminating epidemic meningitis as a public health problem in sub-Saharan Africa through the development, testing, licensure and widespread use of conjugate meningococcal vaccines
• 2001-2002, African public health officials emphasized the cost of the vaccine as a major project constraint to ensure a sustainable supply
PsA produced by SynCo BioPartners, Amsterdam, Netherlands for initial development, then transferred to SIIL.

Serum Institute of India (SIIL) process development and manufacturing.

Lyophilization and stabilization tech transfer from Aerial, France to SIIL.

Conjugation method developed at CBER/FDA, Bethesda, USA, then transferred and scaled-up at SIIL.

Target price US$ 0.50/dose.
Audience Regional Director WHO/AFRO - President Burkina Faso & Press conference, following MenAfriVac prequalification by WHO, June 2010
High level commitment of African Leaders and Partners

MenAfriVac Launch Ceremony 6 Dec 2010 Burkina Faso

Ouagadougou Appeal
(Oct 1996 meeting)

Yaoundé Declaration
(Sept 2008 RC58 meeting)
MenAfriVac roll-out 2010 – 2014
Early achievements 2010-2012

Enormous pay back: No reported case of NmA among the vaccinated
Overall number of meningitis cases 2009-2013 across the African meningitis belt
The Meningitis Vaccine Project (MVP)
A successful vaccine development for Africa

- An exemplary partnership North-South, South-South, with the critical role of a developing country vaccine manufacturer (SIIL)
  - The state-of-the-art development of an affordable vaccine specifically designed to address an unmet major public health need in Africa
  - The diligent registration on this new vaccine paving the way for innovative regulatory pathways
  - A time lag period of 0 year between vaccine licensure and vaccine introduction at public-health scale
  - The development of a strong international scientific network
In collaboration with Health Authorities of 26 countries in Sub-Saharan Africa and of India
KICK MENINGITIS
OUT OF AFRICA